Explore Annogen’s News
Annogen invited to speak at CropIB 2025
We’re thrilled to share that our Founder & CEO, Joris van Arensbergen, has been invited to speak at the prestigious Crop Innovation and Business (CIB) Conference in Cologne, taking place from 30 March – 1 April 2025. Joris will be delivering a talk on Large-scale...
Vacancy: Bioinformatician (32-40h)
We are looking for a highly motivated bioinformatician to join our team (32-40 hours/week, on-site), enthusiastic about science with a strong desire to contribute to cutting-edge research. In this role you will use existing data processing pipelines for the analysis...
UCSF, Annogen Announce Collaboration to Identify Superior Treg-Specific Promoters
UCSF, Annogen Announce Collaboration to Identify Superior Treg-Specific Promoters Annogen, a leader in gene expression engineering, and the prestigious labs of Qizhi Tang and Brian Shy at University of California, San Francisco (UCSF) today announced a collaboration...
Annogen to perform functional genome annotations for KWS to accelerate crop improvement
Einbeck, Germany; Amsterdam, The Netherlands December 5, 2024 KWS SAAT SE & Co. KGaA and Annogen B.V. today announced a partnership in which Annogen will use its FACE™ platform to functionally annotate non-coding variants that are of interest to KWS. FACE™ is an...
Novel Genetic Switches Make Gene Therapies Safer and More Effective -Financieel Dagblad Interview (Nov 2024)
Article as featured in the Financieel Dagblad (Financial Times), 29 November 2024 (link)
Annogen – KeyGene collaboration demonstrates efficacy of the SuRE™ platform to identify gain-of-function in new variants of crops
KeyGene collaboration demonstrates efficacy of the SuRE™ platform to identify gain-of-function in new variants of crops.
Annogen Announces Research Collaboration with Orchard Therapeutics for the Development of CNS-cell Specific Promoters
Annogen today announced a research collaboration with Orchard Therapeutics, a global gene therapy leader, for the identification of immune cell-specific human promoters for use in certain pre-clinical hematopoietic stem cell (HSC) gene therapy programs.
Annogen signs deal in which SuRE™ libraries are used for In-Vivo Capsid screening
Updates - December 2023 Annogen has signed a deal with an undisclosed gene therapy company for an AAV capsid screening project. For this project, Annogen will deliver its SuRE™ barcoding platform and downstream bioinformatics analysis to track tissue-specific biases...
Annogen introduces HEK293-INDX1™ – a clonal HEK293 cell line for inducible expression of toxic proteins such as Rep during AAV production
Updates - October 2023 Annogen is excited to share our latest break through in cellular engineering. We've successfully combined our SuRE™ promoter screening platform and our AIM™ integration site screening platform to establish HEK293 clones with near-zero baseline...
